LAPADULA GIUSEPPE

D'Arminio Monforte, A., Lentini, N., Tavelli, A., Rusconi, S., Sozio, F., Guida, A., et al. (2026). Proportion of newly diagnosed persons with HIV with HIV-RNA greater than/equal to 500 000 copies/mL in 2018–2023 in Italy: data from the ICONA Foundation Cohort Study. CLINICAL MICROBIOLOGY AND INFECTION [10.1016/j.cmi.2026.01.007]. Dettaglio

Micheli, G., Mondi, A., Roen, A., Taramasso, L., Luchetti, I., Mazzotta, V., et al. (2026). Did the COVID-19 pandemic shift the landscape of late HIV diagnosis?. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 165(April 2026) [10.1016/j.ijid.2026.108437]. Dettaglio

Lapadula, G., Soria, A., Antolini, L., Rugova, A., Colella, E., Sabbatini, F., et al. (2026). HBV status modulates transaminase decrease after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people with HIV. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 81(3) [10.1093/jac/dkag045]. Dettaglio

Rugova, A., Ghilardi, G., Colella, E., Squillace, N., Cappelletti, A., Sabbatini, F., et al. (2025). Unexpected HBV reactivation following discontinuation of antiviral prophylaxis in immunosuppressed subjects with previous HBV exposure. In Abstracts from the 17° Italian Conference on AIDS and Antiviral Research (pp.145-146) [10.1136/sextrans-icar-2025.146]. Dettaglio

Gagliardini, R., De Benedittis, S., Tavelli, A., Lapadula, G., Mazzotta, V., Bruzzesi, E., et al. (2025). Effectiveness and predictors of treatment discontinuation of long-acting cabotegravir/rilpivirine in virologically suppressed people with HIV: real-life data from the Icona Cohort. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 80(8), 2169-2178 [10.1093/jac/dkaf184]. Dettaglio